Aileron Therapeutics, Inc. (ALRN)
- Previous Close
4.7500 - Open
4.8800 - Bid --
- Ask --
- Day's Range
4.6500 - 4.9300 - 52 Week Range
1.0100 - 7.4200 - Volume
102,244 - Avg. Volume
66,943 - Market Cap (intraday)
83.674M - Beta (5Y Monthly) 2.24
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4200 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
www.aileronrx.comRecent News: ALRN
Performance Overview: ALRN
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALRN
Valuation Measures
Market Cap
83.67M
Enterprise Value
66.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
12.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.36
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.99%
Return on Equity (ttm)
-26.91%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.73M
Diluted EPS (ttm)
-3.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
17.31M
Total Debt/Equity (mrq)
0.05%
Levered Free Cash Flow (ttm)
-7.62M